Enterovirus D68

Enterovirus D68: Symptoms, Causes, Types, Diagnosis, and Treatments

Enterovirus D68 (EV-D68) has gained public attention in recent years due to its association with respiratory illnesses and neurological complications, particularly in children. As a lesser-known member of the enterovirus family, EV-D68 was first identified in 1962 but remained relatively rare until the early 2000s, when outbreaks began to occur more frequently in the United States and other parts of the world.

This comprehensive guide explores the critical aspects of Enterovirus D68, including its symptoms, causes, types, diagnostic methods, and available treatments.

---

What is Enterovirus D68?

Enterovirus D68 is a non-polio enterovirus belonging to the Picornaviridae family. While enteroviruses typically cause mild illnesses such as hand, foot, and mouth disease or the common cold, EV-D68 has shown a peculiar tendency to cause severe respiratory symptoms and, in rare cases, neurological complications like acute flaccid myelitis (AFM).

EV-D68 primarily affects children but can occasionally cause illness in adults, especially those with weakened immune systems or underlying respiratory conditions like asthma.

---

How is Enterovirus D68 Transmitted?

EV-D68 is spread much like the common cold or flu—through:

• Respiratory droplets when an infected person coughs or sneezes
• Touching contaminated surfaces and then touching your mouth, nose, or eyes
• Close contact with an infected individual

The virus can survive on surfaces for hours, making it highly contagious, especially in schools and daycare centers.

---

Symptoms of Enterovirus D68

The clinical presentation of EV-D68 can range from mild cold-like symptoms to severe respiratory illness. Here’s a detailed breakdown:

Mild to Moderate Symptoms

• Runny nose
• Sneezing
• Cough
• Sore throat
• Low-grade fever
• Muscle aches

Severe Symptoms

• Wheezing
• Shortness of breath
• Rapid breathing
• Bluish lips or fingernails (cyanosis)
• Chest pain
• Difficulty breathing

Neurological Complications (Rare)

One of the most concerning aspects of EV-D68 is its potential to cause acute flaccid myelitis (AFM)—a rare but serious neurological condition that leads to:

• Sudden limb weakness
• Loss of muscle tone
• Facial droop
• Difficulty moving the eyes
• Slurred speech or difficulty swallowing

AFM resembles polio and has been a significant concern during major EV-D68 outbreaks.

---

Causes and Risk Factors

EV-D68 is caused by a single-stranded RNA virus. Though its exact origin and evolution remain under investigation, several factors may contribute to its emergence and severity in certain populations.

1. Seasonal Patterns

Like many respiratory viruses, EV-D68 peaks in late summer and early fall. Outbreaks are more common when schools reopen, increasing the chances of viral spread among children.

2. Immune System Vulnerability

Children under the age of 5 and those with asthma or other respiratory conditions are at a higher risk of developing severe illness due to EV-D68.

3. Underlying Health Conditions

People with compromised immune systems—due to chemotherapy, HIV, or chronic diseases—may experience more severe symptoms and complications.

4. Environmental Factors

Crowded places like daycare centers, schools, and playgrounds are hotspots for enterovirus transmission.

---

Types and Classification of Enteroviruses

EV-D68 is part of a large genus called Enterovirus, which is divided into several species:

• Enterovirus A (e.g., EV-A71)
• Enterovirus B (e.g., Echoviruses, Coxsackie B viruses)
• Enterovirus C (e.g., Polioviruses)
• Enterovirus D (e.g., EV-D68, EV-D70)

EV-D68 belongs to the Enterovirus D species, which is less common than the others but notable for its respiratory and neurological implications.

Although there’s only one serotype of EV-D68, genetic studies have identified multiple lineages or clades, such as:

• Clade A
• Clade B (B1, B2, B3)
• Clade C

These clades may differ in virulence and ability to cause complications like AFM.

---

Diagnosis of Enterovirus D68

Diagnosing EV-D68 can be challenging because its symptoms overlap with many common respiratory viruses. However, accurate diagnosis is essential, especially during outbreaks or when neurological symptoms appear.

1. Clinical Evaluation

Physicians begin with a thorough physical exam and symptom history. Signs of respiratory distress, muscle weakness, or neurological symptoms may prompt further testing.

2. Laboratory Testing

Laboratory tests are used to confirm EV-D68 infection:

• RT-PCR (Reverse Transcriptase Polymerase Chain Reaction): Detects EV-D68 RNA from nasal or throat swabs.
• Viral Culture: Less commonly used but may help in specialized research labs.
• Spinal Tap (Lumbar Puncture): Performed if AFM is suspected to analyze cerebrospinal fluid (CSF).
• MRI Scan: Used to identify spinal cord lesions indicative of AFM.

3. Differential Diagnosis

Other conditions must be ruled out, including:

• Influenza
• Respiratory syncytial virus (RSV)
• COVID-19
• Guillain-Barré syndrome
• Polio (in cases of AFM)

---

Treatment of Enterovirus D68

There is no specific antiviral treatment or vaccine available for EV-D68. Management is primarily supportive, focusing on symptom relief and preventing complications.

1. Supportive Care for Mild Cases

Most individuals recover on their own within a week. Supportive care may include:

• Hydration
• Rest
• Over-the-counter medications for fever and pain (e.g., acetaminophen, ibuprofen)
• Humidifiers and saline nasal sprays for congestion relief

2. Treatment for Severe Respiratory Symptoms

Hospitalization may be required for:

• Severe wheezing or asthma exacerbations
• Respiratory failure
• Low oxygen saturation

Interventions may include:

• Supplemental oxygen
• Bronchodilators (e.g., albuterol)
• Mechanical ventilation in critical cases

3. Management of Neurological Complications (AFM)

There is no proven treatment for AFM, but some therapies may be considered:

• Physical and occupational therapy to restore muscle function
• Intravenous immunoglobulin (IVIG)
• Corticosteroids (controversial and used case-by-case)
• Antiviral medications (experimental)

Prognosis varies: some children recover fully, while others experience long-term disability.

---

Prevention of Enterovirus D68

Prevention is the most effective strategy due to the lack of specific treatment. The following measures can help limit the spread:

1. Hand Hygiene

• Wash hands thoroughly with soap and water, especially after coughing, sneezing, or touching your face.
• Alcohol-based sanitizers are less effective against enteroviruses, so soap and water are preferred.

2. Respiratory Etiquette

• Cover your mouth and nose with a tissue or elbow when sneezing or coughing.
• Dispose of tissues properly.

3. Surface Disinfection

• Regularly clean commonly touched surfaces like doorknobs, toys, and countertops.

4. Stay Home When Sick

• Keep children home from school or daycare when they show symptoms.
• Avoid close contact with sick individuals.

5. Monitoring High-Risk Individuals

• Children with asthma should have an updated action plan and easy access to their inhalers during EV-D68 season.

---

Outbreaks and Public Health Concerns

2014 U.S. Outbreak

In 2014, EV-D68 caused a widespread outbreak in the United States, with over 1,100 confirmed cases. Hospitals reported an unusually high number of children with severe respiratory illness, and several AFM cases were linked to the virus.

Subsequent Outbreaks

Further outbreaks occurred in 2016, 2018, and 2022, with many cases resulting in hospitalization and AFM. The Centers for Disease Control and Prevention (CDC) closely monitors EV-D68 activity, especially during the summer and fall.

Global Spread

Though most data comes from North America, cases have also been reported in Europe, Asia, and Australia, suggesting global circulation of the virus.

---

Current Research and Future Outlook

Ongoing research aims to better understand EV-D68, its connection to AFM, and how best to prevent and treat it.

1. Vaccine Development

Researchers are exploring potential vaccines against EV-D68, similar to how the polio vaccine was developed. However, no vaccine is currently available.

2. Antiviral Medications

Experimental antivirals are under study, but none are yet approved specifically for EV-D68.

3. Genetic Surveillance

Monitoring viral evolution helps in identifying more virulent strains and understanding why some individuals develop neurological complications.

4. Improved AFM Treatment

AFM continues to be a mystery. Research focuses on identifying early biomarkers, optimizing treatment, and improving long-term outcomes.

---

When to Seek Medical Help

Immediate medical attention is necessary if a child or adult experiences:

• Difficulty breathing or rapid breathing
• Severe or persistent wheezing
• Sudden limb weakness or paralysis
• High fever that does not subside
• Cyanosis (bluish skin color)

Early diagnosis and treatment can significantly improve outcomes, particularly in cases of AFM.

---

Frequently Asked Questions (FAQs)

1. Can adults get Enterovirus D68?

Yes, though children are more commonly affected, adults—especially those with chronic respiratory illnesses—can also contract the virus.

2. Is EV-D68 the same as polio?

No, but it can cause polio-like symptoms in rare cases due to its neurological effects, especially when associated with AFM.

3. How long does EV-D68 last?

Mild cases resolve within 7–10 days. More severe cases or complications may take weeks or months for full recovery.

4. Is Enterovirus D68 contagious?

Yes. It spreads easily through respiratory droplets and contaminated surfaces, making it highly contagious.

5. How can I protect my child during an outbreak?

Ensure proper hygiene, keep sick children home, and monitor for signs of severe illness. Children with asthma should follow their treatment plans closely.

---

Conclusion

Enterovirus D68 is a serious public health concern due to its capacity to cause both respiratory and neurological illnesses, particularly in children. While most infections are mild, the potential for severe complications like acute flaccid myelitis makes awareness, prevention, and early diagnosis crucial.

Although there is no vaccine or specific antiviral therapy available, public health measures, proper hygiene, and timely medical care can significantly reduce the risk of infection and its complications.

Staying informed, vigilant, and proactive is key to protecting your family and community from the risks posed by EV-D68.

Frequently Asked Questions (FAQs) About Enterovirus D68

For more details keep visiting our Website & Facebook Page.